AMU, IPC, CRCM
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
Hematopoiesis is the continuous, dynamic and physiological process that ensures the daily production of some 400 billion cells of our blood, a huge activity carried out by a small population of bone marrow cells: hematopoietic stem cells. Since 2012, my laboratory has attempted to understand more about the abnormalities of this process involved in several severe illnesses like Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) through research programs conducted in partnership with the translational medicine team in Hematology led by Professor Vey at the IPC.
By drawing on innovative imaging technological platforms and single-cell molecular biology, we develop animal models to characterize the interactions between normal or pathological hematopoietic stem cells and the medullary microenvironment. These interactions being the cause of resistance to therapies among patients with leukemia, our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
This approach at the interface of clinical, academic and translational research that is very dear to Marseille Immunopole must lead to the setting up of new adjuvant therapeutic strategies to reduce the resistance to therapies and the frequent relapses in these illnesses.#recherche
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
CCI Marseille Provence
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
AMU, AP-HM, CIML, INNATE PHARMA
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.